II. Indications
-
HIV Infection
- Replaced in the U.S. by other nRTIs
III. Mechanism
- Nucleoside Reverse Transcriptase Inhibitor
- Thymidine analogue
- Interferes with viral reverse transcriptase and elongation of the viral DNA chain (as with other nRTIs)
IV. Pharmacokinetics
- Well absorbed from the Gastrointestinal Tract
- Glucuronidase added in the liver
- Excreted by the Kidney
- Crosses the blood-brain barrier and the placenta
V. Efficacy
VI. Dosing
- Taken as part of combination therapy with other Antiretrovirals
- Not to be used as HIV monotherapy (including in pregnancy)
- Adult (or child weight >30 kg)
- Zidovudine 300 mg orally twice daily OR
- Zidovudine 1 mg/kg IV over 1 hour every 4 hours
- Pregnancy - Prevention of vertical transmission
- First, starting at 14 weeks gestation: Take 100 mg orally five times daily until labor
- Peripartum, during labor
- Load 2 mg/kg total body weight IV over 1 hour
- Maintain 1 mg/kg/hour until Umbilical Cord clamped
- Child (age >=4 weeks and weight >=4 kg)
- Weight 4 to 9 kg: 4 mg/kg orally twice daily
- Weight 9 to 30 kg: 9 mg/kg orally twice daily
- Weight >30 kg: 300 mg orally twice daily (adult dosing)
- Infant - Prevention of vertical transmission
- Start within 12 hours of delivery
- Continue until age 6 weeks (four weeks if maternal sustained viral suppression on HAART)
- Original FDA approved protocol
- Give 2 mg/kg (using syringe with 0.1 ml markers) orally every 6 hours
- Alternatively, give 1.5 mg/kg IV over 30 min every 6 hours
- Off Label dosing
- Gestational age >35 weeks: Give 4 mg orally twice daily
- See other references for dosing Gestational age <35 weeks
- Start within 12 hours of delivery
-
Renal Dosing (Adults with Creatinine Clearance <15 ml/min or Hemodialysis)
- Take 100 mg orally every 8 hours OR
- Take 300 mg orally once daily OR
- Give 1 mg/kg IV every 6 to 8 hours
VII. Adverse effects: General
VIII. Adverse Effects: Major Toxicities
- Hepatitis
- Myopathy
-
Bone Marrow suppression
- Anemia (Macrocytosis) (7% late, 1.8% early)
- Leukopenia (Neutropenia) (37% late, 4% early)
- Management of toxicity
- Interrupt treatment
- Results in reversal of Anemia and Neutropenia
- Specific Therapy
- Anemia: Give Erythropoietin
- Neutropenia: Give growth factors
- Persistent Anemia or Neutropenia
- Change therapy
- Interrupt treatment
X. Monitoring
- Advanced disease: Complete Blood Count each month
- Early disease: Complete Blood Count every 2-3 months
XI. Drug Interactions
- CMV Prophylaxis agents (Ganciclovir or Valganciclovir)
- Increased Bone Marrow suppression risk
-
Nevirapine
- Increased Granulocytopenia risk (esp. children)
XII. Resources
XIII. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- (1998) Med Lett Drugs Ther 40(1041):115 [PubMed]
- (2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
- Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]